127 related articles for article (PubMed ID: 27014271)
21. Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis.
Gonçalves ED; Souza PS; Lieberknecht V; Fidelis GS; Barbosa RI; Silveira PC; de Pinho RA; Dutra RC
Autoimmunity; 2016; 49(2):132-42. PubMed ID: 26703077
[TBL] [Abstract][Full Text] [Related]
22. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery.
Samoilova EB; Horton JL; Chen Y
Cell Immunol; 1998 Sep; 188(2):118-24. PubMed ID: 9756642
[TBL] [Abstract][Full Text] [Related]
23. Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis.
Valentin-Torres A; Savarin C; Hinton DR; Phares TW; Bergmann CC; Stohlman SA
J Neuroinflammation; 2016 Feb; 13():46. PubMed ID: 26906225
[TBL] [Abstract][Full Text] [Related]
24. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.
Mandolesi G; Gentile A; Musella A; Fresegna D; De Vito F; Bullitta S; Sepman H; Marfia GA; Centonze D
Nat Rev Neurol; 2015 Dec; 11(12):711-24. PubMed ID: 26585978
[TBL] [Abstract][Full Text] [Related]
25. Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis.
Berard JL; Zarruk JG; Arbour N; Prat A; Yong VW; Jacques FH; Akira S; David S
Glia; 2012 Jul; 60(7):1145-59. PubMed ID: 22499213
[TBL] [Abstract][Full Text] [Related]
26. Differential DM20 mRNA expression distinguishes two distinct patterns of spontaneous recovery from murine autoimmune encephalomyelitis.
Mathisen PM; Kawczak JA; Yu M; Johnson JM; Tuohy VK
J Neurosci Res; 2001 Jun; 64(5):542-51. PubMed ID: 11391709
[TBL] [Abstract][Full Text] [Related]
27. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
[TBL] [Abstract][Full Text] [Related]
28. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
[TBL] [Abstract][Full Text] [Related]
29. Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
Sher F; Amor S; Gerritsen W; Baker D; Jackson SL; Boddeke E; Copray S
Cell Transplant; 2012; 21(9):1883-97. PubMed ID: 22469520
[TBL] [Abstract][Full Text] [Related]
30. Acquired channelopathies as contributors to development and progression of multiple sclerosis.
Schattling B; Eggert B; Friese MA
Exp Neurol; 2014 Dec; 262 Pt A():28-36. PubMed ID: 24656770
[TBL] [Abstract][Full Text] [Related]
31. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Ruffini F; Rossi S; Bergamaschi A; Brambilla E; Finardi A; Motta C; Studer V; Barbieri F; De Chiara V; Hayardeny L; Comi G; Centonze D; Martino G
Mult Scler; 2013 Jul; 19(8):1084-94. PubMed ID: 23232603
[TBL] [Abstract][Full Text] [Related]
32. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.
Eltayeb S; Berg AL; Lassmann H; Wallström E; Nilsson M; Olsson T; Ericsson-Dahlstrand A; Sunnemark D
J Neuroinflammation; 2007 May; 4():14. PubMed ID: 17484785
[TBL] [Abstract][Full Text] [Related]
33. GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice.
Orsini H; Araujo LP; Maricato JT; Guereschi MG; Mariano M; Castilho BA; Basso AS
Brain Behav Immun; 2014 Mar; 37():177-86. PubMed ID: 24362236
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS.
Ellwardt E; Zipp F
Exp Neurol; 2014 Dec; 262 Pt A():8-17. PubMed ID: 24530639
[TBL] [Abstract][Full Text] [Related]
35. Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis.
Markoullis K; Sargiannidou I; Gardner C; Hadjisavvas A; Reynolds R; Kleopa KA
Glia; 2012 Jul; 60(7):1053-66. PubMed ID: 22461072
[TBL] [Abstract][Full Text] [Related]
36. Evidence that Fas and FasL contribute to the pathogenesis of experimental autoimmune encephalomyelitis.
Dittel BN
Arch Immunol Ther Exp (Warsz); 2000; 48(5):381-8. PubMed ID: 11140465
[TBL] [Abstract][Full Text] [Related]
37. The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability.
Moliné-Velázquez V; Ortega MC; Vila del Sol V; Melero-Jerez C; de Castro F; Clemente D
Neurobiol Dis; 2014 Jul; 67():149-64. PubMed ID: 24709559
[TBL] [Abstract][Full Text] [Related]
38. Hippocampal function is compromised in an animal model of multiple sclerosis.
Novkovic T; Shchyglo O; Gold R; Manahan-Vaughan D
Neuroscience; 2015 Nov; 309():100-12. PubMed ID: 25795599
[TBL] [Abstract][Full Text] [Related]
39. MOG-induced experimental autoimmune encephalomyelitis in the rat species triggers anti-neurofascin antibody response that is genetically regulated.
Flytzani S; Guerreiro-Cacais AO; N'diaye M; Lindner M; Linington C; Meinl E; Stridh P; Jagodic M; Olsson T
J Neuroinflammation; 2015 Oct; 12():194. PubMed ID: 26511327
[TBL] [Abstract][Full Text] [Related]
40. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE.
Brochet B; Deloire MS; Touil T; Anne O; Caillé JM; Dousset V; Petry KG
Neuroimage; 2006 Aug; 32(1):266-74. PubMed ID: 16650776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
